The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with 90Y-DOTATOC. 90Y-DOTATOC should be further investigated in this setting.
Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group / T. De Pas, L. Bodei, G. Pelosi, F. de Braud, G. Villa, R. Capanna, G. Paganelli. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 88:5(2003), pp. 645-647.
Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group
G. Pelosi;F. de Braud;
2003
Abstract
The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with 90Y-DOTATOC. 90Y-DOTATOC should be further investigated in this setting.File | Dimensione | Formato | |
---|---|---|---|
88-6600823a.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
97.17 kB
Formato
Adobe PDF
|
97.17 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.